T1	Participants 39 118	previously treated patients with refractory advanced non-small-cell lung cancer
T2	Participants 374 445	patients with locally advanced or metastatic non-small-cell lung cancer
T3	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T4	Participants 1929 1971	never-smokers and patients of Asian origin
T5	Participants 1236 1268	812 patients with adenocarcinoma
T6	Participants 1540 1552	Asian origin
T7	Participants 1440 1453	never-smokers
